



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.

SERIAL NO.

01414/1/US (Pfizer Ref. 27788A/USA)

10/722,104

APPLICANT

Daniel P. Becker, et al.

FILING DATE

GROUP

11/25/2003

1614

## U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date

## FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation	
						Yes	No
24.	DP	WO 99/09000	2/25/99	PCT	C07C 235/00		
25.		WO 99/25687	5/27/99	PCT	C07D 211/66		
26.		WO 99/29667	6/17/99	PCT	C07D 211/16		
27.		WO 00/46221	8/10/00	PCT	C07D 405/12		
28.		WO 00/50396	8/31/00	PCT	C07D 211/66		
29.		WO 00/59874	10/12/00	PCT	C07C 259/06		
30.		WO 00/69821	11/23/00	PCT	C07D 211/66		
31.		WO 02/092588	11/21/02	PCT	C07D 309/08		
32.		WO 03/091247	11/6/03	PCT	C07D 407/12		
33.		WO 2004/000811	12/31/03	PCT	C07D 213/34		
34.		EP 0 780 386	6/25/97	Europe	C07D 309/08		
35.		EP 0 994 104	4/19/00	Europe	C07C 317/44		
36.		EP 1 081 137	3/07/01	Europe	C07D 211/96		

Examiner: *Sarah Peeling*Date Considered: *06/08/06*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LV 317349955 US

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 2 of 3</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	01414/1/US (Pfizer Ref. 27788A/USA)	10/722,104
	APPLICANT	
	Daniel P. Becker, et al.	
	FILING DATE	GROUP
	11/25/2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
37.	DP	Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
38.		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).
39.		Freije et al., <i>Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas</i> , J BIOL. CHEM., 269(24):16766-16773 (1994).
40.		Gearing et al., <i>Processing of tumour necrosis factor-<math>\alpha</math> precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
41.		Gu et al., <i>S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death</i> , SCIENCE, 297:1186-90 (2002).
42.		Kenyon et al., <i>A model of angiogenesis in the mouse cornea</i> , INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996).
43.		Knight et al., <i>A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases</i> , FEBS LETT., 296(3):263-266 (1992).
44.		Kuzmic et al., <i>High-throughput enzyme kinetics: Simultaneous determination of tight-binding inhibition constants and enzyme concentration</i> , ANAL. BIOCHEM., 286(1):45-50 (2000).
45.		Luckow et al., <i>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli</i> , J. VIROL., 67:4566-4579 (1993).
46.		McGeehan et al., <i>Regulation of tumour necrosis factor-<math>\alpha</math> processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
47.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).
48.		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).
49.		Reboul et al., <i>The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
50.		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
51.		Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).

Examiner: <i>Danah Peeling</i>	Date Considered: <i>06/08/06</i>
--------------------------------	----------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 3 of 3</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	01414/1/US (Pfizer Ref. 27788A/USA)	10/722,104
	APPLICANT	
	Daniel P. Becker, et al.	
	FILING DATE	GROUP
	11/25/2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
52.	DP	Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
53.	-	Search Report and Preliminary Examination Report for International Application No. PCT/US03/37942

Examiner: Sarah Paulinger	Date Considered: 06/08/06
---------------------------	---------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.

01414/1/US (Pfizer Ref. 27788A/USA)

SERIAL NO.

10/722,104

APPLICANT

Daniel P. Becker, et al.

FILING DATE

11/25/2003

GROUP

1614

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date
1.	DP	4,595,700	6/17/86	Donald et al.	514/616	2/21/85
2.		6,013,649	1/11/00	Freskos et al.	514/237.8	7/22/97
3.		6,300,514	10/9/01	Takahashi et al.	549/462	1/15/99
4.		6,448,250	9/10/02	DeCrescenzo et al.	546/252	2/7/00
5. (office action and notices of allowances enclosed)		6,541,489, including the 12/17/01 Office action, 5/16/02 notice of allowance, and 11/8/02 notice of allowance	4/1/03	Barta et al.	514/330	7/31/00
6.		6,683,093	1/27/04	Barta et al.	514/316	11/21/01
7. (Office action and notice of allowance enclosed)		6,750,233, including 11/18/02 Office action and 5/9/03 notice of allowance	11/28/02	Barta et al.	514/336	9/17/01
8. (allowed claims and notice of allowance enclosed)		Publ. No. 2004-0048852 (Appl. No. 10/337,942), including allowed claims and 2/13/04 notice of allowance	3/11/04	Barta et al.	514/317	1/7/03
9. (enclosed)		Abandoned Appl. No. 09/311,837, including 6/14/00 Office action, 5/3/01 Office action, 11/20/03 Office action, and 7/28/04 Office action		Barta et al.		5/14/99
10. (Office actions enclosed)		Abandoned Appl. Publ. No. 20010039287 (Appl. No. 09/256,948), including 6/1/00 Office action and 3/29/01 Office action		Barta et al.	514/330	2/24/99

Examiner: Sarah Peeling

Date Considered: 06/08/06

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

57

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.

01414/1/US (Pfizer Ref.  
27788A/USA)

SERIAL NO.

10/722,104

APPLICANT

Daniel P. Becker, et al.

FILING DATE

11/25/2003

GROUP

1614

11. (Office actions enclosed)	Abandoned Appl. Publ. No. 20010014688 (Appl. No. 09/191,129), including 12/29/99 Office action, 8/7/00 Office action, 2/16/01 Office action, 11/26/01 Office action, and 6/25/02 Office action	Barta et al.	514/318	11/13/98
12. (enclosed)	Abandoned Appl. No. 09/186,410, including 11/19/99 Office action	Barta et al.		11/13/98

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
13.	DP	WO 90/05719	05/31/90	PCT	C07C 323/62		
14.		WO 93/20047	10/14/93	PCT	C07C 317/44		
15.		WO 94/02466	02/03/94	PCT	C07D 221/14		
16.		WO 94/24140	10/27/94	PCT	C07H 13/04		
17.		WO 95/09841	4/13/95	PCT	C07C 323/60		
18.		WO 95/13289	5/11/95	PCT	A61K 9/127		
19.		WO 95/29892	11/9/95	PCT	C07D 207/327		
20.		WO 96/06074	2/29/96	PCT	C07C 259/06		
21.		WO 96/11209	4/18/96	PCT	C07K 5/06		
22.		WO 97/20824	6/12/97	PCT	C07D 241/04		
23.		WO 97/24117	7/10/97	PCT	A61K 31/19		

Examiner:

*Sarah R. King*

Date Considered:

*06/08/06*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM HDP-1449 (Based on Form PTO-1449)</b>  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 3 of 3	<b>ATTORNEY DOCKET NO.</b> 01414/1/US (Pfizer Ref. 27788A/USA)	<b>SERIAL NO.</b> 10/722,104
	<b>APPLICANT</b> Daniel P. Becker, et al.	
	<b>FILING DATE</b> 11/25/2003	<b>GROUP</b> 1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.